SPECTRI Trial in Chevy Chase

“ Dr. Richard Garfinkle presented the protocol of the ongoing SPECTRI trial to eye specialists in Northern Virginia.  SPECTRI is an ongoing clinical trial examining the role of lampalizumab for the treatment of geographic atrophy in macular degeneration.  This represents the first major, interventional trial in dry macular degeneration.  The Retina Group of Washington is the only practice in the DC metropolitan area participating in this pivotal, cutting-edge trial. “

 

 

For more about SPECTRI trial click here.

Eye Surgery in Chevy Chase

Chevy Chase Retina

Eye surgery in Chevy Chase

Eye surgery in Chevy Chase

Are you suffering from an advanced stage of macular degeneration? If so there is still an effective treatment option available to help restore your vision. If you are interested in eye surgery in Chevy Chase that involves a CentraSight implant, contact us at The Retina Group of Washington to see if you may be a good candidate.

At our eye care practice we are happy to have 26 of the most respected and highly-trained ophthalmologists on staff. Our eye care practice focuses on care of the retina; we also treat eye diseases of other parts of the eye as well. Our expert ophthalmologists in our Chevy Chase office are: Dr. Daniel M. Berinstein; Dr. William F. Deegan, III; Dr. Richard A. Garfinkel; Dr. T. Mark Johnson; Dr. Michael M. Lai; Dr. Robert P. Murphy; Dr. Gayatri S. Reilly; and Dr. Reginald J. Sanders. If you are suffering from end-stage age-related macular degeneration (AMD) the Central Sight treatment program may be able to help you. This program features a tiny telescope which is implanted into the eye. It will improve the vision and life of patients who are affected by end-stage AMD. This is an FDA approved medical device. Patients come to our practice to have this device inserted into the eye by eye surgery in Chevy Chase.

This telescope will help in reducing the impact of the blind spot on the macula caused by end-stage AMD. This telescope will project the object the patient is trying to see onto the healthy, functioning area of the retina. This implant is about the size of a pea. It will improve both the distance and near vision of patients who have lost central vision to end-stage AMD. Potential candidates for the telescope implant procedure must have irreversible end-stage AMD. It does not matter if the AMD is of the dry or wet form. Drug treatment must no longer work to improve the patient’s vision. There could not have been any cataract surgery in the eye. And certain age, vision and cornea health requirements must be met. If our ophthalmologist feels you are a possible good candidate, your vision will be tested using an external telescope simulator. This CentraSight telescope is only inserted into one eye, so our patient along with our doctor will need to determine which eye should be treated. If you would like more information about this eye surgery in Chevy Chase, contact us today.

5454 Wisconsin Ave., Suite 650
Chevy Chase, MD 20815
(301) 656-8100

RGW Selects Modernizing Medicine, Inc., for EMA

Modernizing Medicine, Inc., the creator of the Electronic Medical Assistant® (EMA™), a cloud-based, iPad native, specialty-specific electronic medical record (EMR) system, announced today that The Retina Group of Washington has selected EMA Ophthalmology to replace its legacy EMR solution. Use of the highly specialized EMR system will help streamline physician workflows and improve patient care across the entire practice.
With 26 physicians working across 14 offices, The Retina Group of Washington is one of the largest and most highly respected retinal and macular practices in the country. The Retina Group of Washington is well known for its extensive experience and sub-specialty expertise of its leading physicians and surgeons. Deeply committed to the advancement of care, the group is constantly conducting cutting-edge research and administers a Fellowship program to train future ophthalmologists.
“As one of the leading retinal practices in the country, we constantly look for ways to make our physicians’ lives easier and improve care,” said Dr. Michael Rivers, current Board member at The Retina Group of Washington and head of their EMR system selection committee.
For more information click here.

Macular Degeneration in Chevy Chase

Dr. Richard Garfinkle presented a talk titled “Age-Related Macular Degeneration:  New strategies for minimizing and managing vision loss.”  at the Chevy Chase Village Center as part of the “Chevy Chase at Home” community group.

For more information on macular degeneration click here.

Surgical Outcomes in Macular Pucker Patients

Dr. Reilly  published a paper in the journal Retina examining the outcomes of vitrectomy surgery in patients with macular pucker and good visual acuity.  They specifically examined the visual outcomes in patients with symptomatic macular pucker with relatively good pre-operative visual acuity ( better than 20/50 ).  At one year follow up they showed a significant improvement in visual acuity in patients undergoing surgery.  This study confirmed previous study observations that progression of cataract is common after vitrectomy.  Cataracts are treatable with outpatient surgery.  The journal Retina is a leading, peer-reviewed journal in ophthalmology and a source for innovative research in the field of vitreo-retinal surgery world-wide.

 

Read the Full Article Here

Top Retinal Ophthalmologist In Chevy Chase

Drs.  Reginald J. Sanders and William F. Deegan were selected by their colleagues in the medical field as “Top Doctors” in Ophthalmology as part of the 2015 “Top Doctors” published in the September issue of Washingtonian.  The bi-annual survey,  conducted for the first time online, solicited nominations from more than 12,000 physicians throughout D.C., Maryland and Virginia.  The list is designed to help readers find the best medical care in their communities, including primary care doctors and those specialists whom patients choose for themselves.

Retinal Vein Occlusion in Young Patients

The management of retinal vein occlusion (RVO) has changed dramatically over the last 3 decades since the results of the Branch Vein Occlusion Study (BVOS) and Central Vein Occlusion Study (CVOS) were published in the 1980s and 1990s.

While most patients who present with RVO are 60 years of age or older, young patients can pose particular diagnostic and treatment challenges.

In this installment of Practical Retina, current RGW retina fellow Dr. Luke Lindsell and Dr. Michael Lai from Washington, D.C., address what should be included in an appropriate diagnostic work-up for younger patients who present with RVO, provide pearls for detecting uncommon underlying systemic etiologies, and review their treatment paradigm.

You can read about it in their article entitled “Current concepts in managing retinal vein occlusion in young patients” for the July/August 2015 issue of the journal Ophthalmic Surgery Lasers & Imaging Retina.

Click here to read more.

Source: Ophthalmic Surgery, Lasers and Imaging Retina July 2015 – Volume 46 · Issue 7: 695-701

Dr. Johnson quoted in MEDSCAPE Article on Diabetic Retinopathy at the Point of Primary Care

Below is an excerpt from the article quoting Dr. Johnson as a consulting retinal surgeon. Click on the link below to read the full article:

 

Dr Silva noted, however, that the cost of ultrawide field imaging devices at the present time “is prohibitive,” especially in places with small populations and a limited number of diabetes patients. But prices will come down in time, he added.

Asked to comment, T Mark Johnson, MD, FRCSC, an attending surgeon at the Retina Group of Washington, DC, who was not involved in the study, agreed that the current costs of the cameras used in ultrawide field imaging, are “significant” and could therefore limit their use in screening programs.

And he claims that past studies have suggested that even three-field photography (just taking photos of the posterior pole of the retina) may be as good as ultrawide field imaging for screening for significant diabetic retinopathy. Therefore, more research is needed to justify the added costs of ultrawide field imaging, he pointed out.

See more: http://www.medscape.com/viewarticle/846470